-
公开(公告)号：US20210238266A1
公开(公告)日：2021-08-05
申请号：US17098076
申请日：2020-11-13
发明人： Christopher Breuer , Narutoshi Hibino , Vidu Garg , Cameron Best
IPC分类号： C07K16/18 , A61L27/54 , A61L31/16 , A61K31/713 , A61L27/36 , A61K9/00 , A61K31/7105 , A61L29/16 , A61L27/50 , A61K45/06
摘要： Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage. Compositions and methods for inhibition of the expression and function of the LYST protein are described. The compositions and methods can be useful for the modulation of immune processes that contribute to formation of neointima and fibroproliferative disorders by altering macrophage, platelet and natural killer cell function to create a pro-regenerative immune response.
-
公开(公告)号：US11541149B2
公开(公告)日：2023-01-03
申请号：US15781679
申请日：2016-12-12
IPC分类号： A61L27/38 , A61L27/18 , A61L27/20 , A61L27/24 , A61L27/50 , D01D5/00 , B33Y10/00 , B33Y80/00 , A61L27/54 , A61L27/58
摘要： It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.
-
公开(公告)号：US20170073401A1
公开(公告)日：2017-03-16
申请号：US15308445
申请日：2015-05-04
发明人： Christopher Breuer , Narutoshi Hibino , Vidu Garg , Cameron Best
IPC分类号： C07K16/18 , A61L27/54 , A61K31/713 , A61K45/06 , A61L31/16
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K31/713 , A61K45/06 , A61K2039/505 , A61L27/36 , A61L27/507 , A61L27/54 , A61L29/16 , A61L31/16 , A61L2300/256 , A61L2300/258 , A61L2300/42 , C07K2317/76
摘要： Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage. Compositions and methods for inhibition of the expression and function of the LYST protein are described. The compositions and methods can be useful for the modulation of immune processes that contribute to formation of neointima and fibroproliferative disorders by altering macrophage, platelet and natural killer cell function to create a pro-regenerative immune response.
摘要翻译： 在组织损伤部位过度或反复激活炎症和促凝血机制有助于发展瘢痕组织，从而导致内膜增生和纤维化疾病。 已经确定，LYST蛋白的抑制与组织损伤部位的炎症反应减少和血小板活化降低有关。 描述了用于抑制LYST蛋白的表达和功能的组合物和方法。 组合物和方法可用于通过改变巨噬细胞，血小板和自然杀伤细胞功能以产生促再生免疫应答而有助于形成新内膜和纤维增生性疾病的免疫过程的调节。
-
公开(公告)号：US12115282B2
公开(公告)日：2024-10-15
申请号：US18063600
申请日：2022-12-08
IPC分类号： A61L27/38 , A61L27/18 , A61L27/20 , A61L27/24 , A61L27/50 , A61L27/54 , A61L27/58 , B33Y10/00 , B33Y80/00 , D01D5/00
CPC分类号： A61L27/3834 , A61L27/18 , A61L27/20 , A61L27/24 , A61L27/507 , A61L27/54 , A61L27/58 , B33Y10/00 , B33Y80/00 , D01D5/0076 , A61L2300/41 , A61L2300/414 , A61L2300/416 , A61L27/18 , C08L67/04 , A61L27/18 , C08L77/00 , A61L27/18 , C08L85/02
摘要： It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.
-
公开(公告)号：US10895020B2
公开(公告)日：2021-01-19
申请号：US15755149
申请日：2016-08-26
申请人： CHILDREN'S NATIONAL MEDICAL CENTER , RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL , NANOFIBER SOLUTIONS LLC
发明人： Axel Krieger , Narutoshi Hibino , Jed Johnson , Justin Opfermann , Carolyn Cochenour Dorgan , Christopher K. Breuer
IPC分类号： B29C33/44 , B29C33/48 , B29C33/52 , D01D5/00 , A61F2/06 , B29C64/106 , B29C64/112 , B29C33/38 , B33Y50/00 , B33Y80/00 , B29C64/386 , B29L31/00 , B33Y10/00 , A61B34/10
摘要： A method for generating a electro spun fiber medical implant including determining dimensions of a portion of anatomy of a patient corresponding to the electro spun fiber medical implant via medical imaging, generating a model of the portion of the anatomy based on the dimensions, the model including one or more solid areas and one or more void areas encompassed within the one or more solid areas, inverting the model to generate a mandrel model, the mandrel model generated based on the one or more void areas, generating the mandrel based on the mandrel model, the mandrel including at least one electrically conductive material therein, and applying an electro-spinning process to the mandrel to generate the electro spun fiber medical implant which circumscribes the mandrel, wherein the mandrel is removable from within the electro spun fiber medical implant after a disassembly process.
-
公开(公告)号：US20180353649A1
公开(公告)日：2018-12-13
申请号：US15781679
申请日：2016-12-12
CPC分类号： A61L27/3834 , A61L27/18 , A61L27/20 , A61L27/24 , A61L27/507 , A61L27/54 , A61L27/58 , A61L2300/41 , A61L2300/414 , A61L2300/416 , B33Y10/00 , B33Y80/00 , D01D5/0076 , C08L67/04 , C08L77/00 , C08L85/02
摘要： It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
